Freedom Investment Management Inc. Boosts Stake in Moderna, Inc. $MRNA

Freedom Investment Management Inc. raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 16.9% in the second quarter, Holdings Channel.com reports. The fund owned 14,759 shares of the company’s stock after buying an additional 2,137 shares during the quarter. Freedom Investment Management Inc.’s holdings in Moderna were worth $407,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in Moderna by 1.8% during the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock valued at $54,382,000 after acquiring an additional 34,034 shares during the period. Wealthfront Advisers LLC boosted its position in shares of Moderna by 143.3% in the first quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company’s stock worth $879,000 after buying an additional 18,268 shares during the period. FORA Capital LLC boosted its position in shares of Moderna by 31.7% in the first quarter. FORA Capital LLC now owns 97,072 shares of the company’s stock worth $2,752,000 after buying an additional 23,344 shares during the period. Jump Financial LLC boosted its position in shares of Moderna by 5,590.0% in the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after buying an additional 886,567 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after buying an additional 285,662 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Evercore ISI set a $32.00 target price on Moderna in a research report on Friday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Bank of America decreased their target price on Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. decreased their target price on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $36.86.

Moderna Stock Performance

NASDAQ:MRNA opened at $26.74 on Monday. Moderna, Inc. has a one year low of $23.15 and a one year high of $57.69. The business’s 50-day simple moving average is $25.94 and its 200 day simple moving average is $27.15. The stock has a market cap of $10.44 billion, a price-to-earnings ratio of -3.55 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. During the same quarter in the previous year, the firm posted ($3.33) earnings per share. The company’s revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.